Leadership

Led by an experienced team

Management Team
Board of Directors

We have built a management team with experience in all aspects of biopharmaceutical development and commercialization to drive the company forward.

Emil D. Kakkis, M.D., Ph.D.

Founder, President and Chief Executive Officer, Ultragenyx

Camille L. Bedrosian, M.D.

Chief Medical Officer and Executive Vice President

Mardi C. Dier

Chief Financial Officer and Executive Vice President

Erik Harris

Chief Commercial Officer and Executive Vice President

Dennis Huang

Chief Technical Operations Officer and Executive Vice President

Thomas Kassberg

Chief Business Officer and Executive Vice President

Ernie Meyer

Chief Human Resources Officer and Executive Vice President

Karah Parschauer

Chief Legal Officer and Executive Vice President

John Pinion

Chief Quality Operations Officer and Executive Vice President, Translational Sciences

Our Board provides us with strategic guidance as we advance our mission of making a meaningful difference in the lives of patients with rare genetic diseases.

Emil D. Kakkis, M.D., Ph.D.

Founder, President and Chief Executive Officer, Ultragenyx

Daniel G. Welch

Chairperson
Biotechnology Executive

Deborah Dunsire, M.D.

President and Chief Executive Officer, Lundbeck

Lars Ekman, M.D., Ph.D.

Executive Partner, Sofinnova Ventures

Matthew K. Fust

Biotechnology Executive

Michael Narachi

President, Chief Executive Officer and Director, CODA Biotherapeutics, Inc.

Amrit Ray, M.D., M.B.A.

Chief Patient Officer, Biohaven Pharmaceuticals

Corsee Sanders, Ph.D.

Biotechnology Executive

Shehnaaz Suliman, M.D., MBA, M.Phil.

Chief Executive Officer, ReCode Therapeutics

Our success to date is driven by our productive collaborations with academia and industry.

Learn about the companies with whom we are collaborating